New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2013
07:09 EDTAPRIApricus Biosciences elects Kleanthis Xanthopoulos, Ph.D. as chairman
Apricus Biosciences announced that Kleanthis G. Xanthopoulos, Ph.D. has been elected as chairman of the company's board. Dr. Xanthopoulos succeeds Rusty Ray in the chairman role. Ray will continue to serve as a director and will assume key roles on the company's audit, compensation and corporate governance committees of the board. Dr. Xanthopoulos has been a member of the Apricus Board since 2011.
News For APRI From The Last 14 Days
Check below for free stories on APRI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 3, 2014
08:06 EDTAPRIApricus Biosciences granted national phase approval for Vitaros in Luxembourg
Apricus Biosciences (APRI) announced that the Ministry of Health of Luxembourg has granted national phase approval to Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction. The company has now received a total of nine national phase approvals for Vitaros®, including Luxembourg, Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom following its broad approval by European health authorities in June 2013. Apricus has an exclusive commercialization partnership in place with Hexal AG, an affiliate within the Sandoz Division of the Novartis (NVS), for the commercialization of Vitaros in several European countries, including Luxembourg.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use